Management of Drug-Susceptible and Drug-Resistant Tuberculosis — Updated Guidelines

New guidelines recommend a 4-month regimen as comparable to a 6-month regimen for most cases of drug-susceptible tuberculosis and a 6-month regimen for selected cases of drug-resistant tuberculosis.

Sponsoring Organizations: American Thoracic Society, Centers for Disease Control, European Respiratory Society, Infectious Diseases Society of America

Background and Objective

An international expert panel reviewed recent literature, conference presentations, and safety reports to update the 2022 World Health Organization and 2016/2017 ATS/CDC/IDSA recommendations on management of drug-susceptible and drug-resistant tuberculosis (TB)

Key Recommendations

A 4-month regimen (2 months of isoniazid, rifapentine, pyrazinamide, and moxifloxacin followed by 2 months of isoniazid, rifapentine, and moxifloxacin [2HPZM/2HPM]) is generally as safe and efficacious as a 6-month regimen (2 months of isoniazid, rifampin, pyrazinamide, and ethambutol followed b…

Reviewing Author

Richard T. Ellison III, MD

Disclosures

Consult/Advisory BoardAcurx Pharmaceuticals, LLC;

Grant/Research SupportDoctors Company Foundation, Massachusetts Department of Public Health